Compare Aurobindo Pharma with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DR. DATSONS LABS - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DR. DATSONS LABS AUROBINDO PHARMA/
DR. DATSONS LABS
 
P/E (TTM) x 13.7 -10.9 - View Chart
P/BV x 2.5 0.2 1,555.5% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   DR. DATSONS LABS
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
DR. DATSONS LABS
Mar-14
AUROBINDO PHARMA/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs830126 660.8%   
Low Rs52731 1,705.8%   
Sales per share (Unadj.) Rs333.9133.0 251.1%  
Earnings per share (Unadj.) Rs40.40.2 26,618.2%  
Cash flow per share (Unadj.) Rs51.86.6 783.3%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.1128.8 184.1%  
Shares outstanding (eoy) m585.9131.66 1,850.6%   
Bonus/Rights/Conversions ESOPFCCB-  
Price / Sales ratio x2.00.6 345.4%   
Avg P/E ratio x16.8516.1 3.3%  
P/CF ratio (eoy) x13.111.8 110.7%  
Price / Book Value ratio x2.90.6 471.1%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,5692,477 16,047.9%   
No. of employees `00017.9NA-   
Total wages/salary Rs m25,84956 46,158.4%   
Avg. sales/employee Rs Th10,956.9NM-  
Avg. wages/employee Rs Th1,447.7NM-  
Avg. net profit/employee Rs Th1,324.3NM-  
INCOME DATA
Net Sales Rs m195,6364,211 4,646.4%  
Other income Rs m1,55379 1,973.6%   
Total revenues Rs m197,1894,289 4,597.3%   
Gross profit Rs m39,519569 6,950.3%  
Depreciation Rs m6,680204 3,267.9%   
Interest Rs m2,626430 610.4%   
Profit before tax Rs m31,76713 250,134.6%   
Minority Interest Rs m270-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2696 119,155.7%   
Profit after tax Rs m23,6455 492,604.2%  
Gross profit margin %20.213.5 149.6%  
Effective tax rate %22.948.0 47.6%   
Net profit margin %12.10.1 10,601.9%  
BALANCE SHEET DATA
Current assets Rs m153,6456,852 2,242.5%   
Current liabilities Rs m120,4296,711 1,794.6%   
Net working cap to sales %17.03.3 507.0%  
Current ratio x1.31.0 125.0%  
Inventory Days Days135161 84.1%  
Debtors Days Days64318 20.0%  
Net fixed assets Rs m103,9093,673 2,829.0%   
Share capital Rs m586317 185.1%   
"Free" reserves Rs m138,3223,761 3,677.8%   
Net worth Rs m138,9084,078 3,406.7%   
Long term debt Rs m1,8001,671 107.7%   
Total assets Rs m264,54412,633 2,094.1%  
Interest coverage x13.11.0 1,272.2%   
Debt to equity ratio x00.4 3.2%  
Sales to assets ratio x0.70.3 221.9%   
Return on assets %9.93.4 288.4%  
Return on equity %17.00.1 14,459.9%  
Return on capital %23.87.7 310.6%  
Exports to sales %49.622.9 216.8%   
Imports to sales %18.814.3 131.4%   
Exports (fob) Rs m97,091964 10,071.7%   
Imports (cif) Rs m36,741602 6,104.2%   
Fx inflow Rs m97,316964 10,095.1%   
Fx outflow Rs m40,589607 6,685.8%   
Net fx Rs m56,727357 15,894.4%   
CASH FLOW
From Operations Rs m16,2201,345 1,206.1%  
From Investments Rs m-28,768-2,256 1,275.4%  
From Financial Activity Rs m19,191-1,200 -1,599.5%  
Net Cashflow Rs m6,656-2,111 -315.4%  

Share Holding

Indian Promoters % 54.1 4.5 1,194.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 0.0 -  
FIIs % 27.7 1.4 2,051.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 94.1 10.8%  
Shareholders   69,601 20,807 334.5%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   TORRENT PHARMA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALKEM LABORATORIES  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Slow Economy? There's Still Good Money to Be Made in the Markets(Podcast)

Indian stock markets mostly remained in the negative zone during the week except for Wednesday.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years)(Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

Will Algo Traders Take Away All Your Profits?(Fast Profits Daily)

Feb 11, 2020

How to fight back against algo trading systems.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 20, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS